Gujarat Themis Biosyn Ltd

Guj. Themis Bio., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting shifts in key analytical parameters. This adjustment highlights evolving perspectives on the company’s valuation, financial trends, quality metrics, and technical outlook amid a backdrop of mixed performance indicators.

Gujarat Themis Biosyn, a notable player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across various timeframes. Recent market data reveals a mild adjustment in the company’s technical parameters, coinciding with a day change of -3.73% and a current price of ₹420.75, down from the previous close of ₹437.05.

Gujarat Themis Biosyn has reported significant financial improvements for the quarter ending September 2025, achieving record net sales of Rs 42.35 crore and a PBDIT of Rs 20.95 crore. The company also demonstrated strong operational efficiency with a 49.47% operating profit margin and impressive profitability metrics.

Gujarat Themis Biosyn Ltd., a Vapi-based pharmaceutical manufacturer, delivered an exceptional performance in Q2 FY26, posting net profit of ₹14.26 crores—a 34.92% quarter-on-quarter surge and 21.98% year-on-year growth. The company's shares have responded enthusiastically, trading at ₹454.25 as of November 10, representing a 0.89% single-day gain and maintaining a commanding 40.20% annual return despite the stock's premium valuation of 111 times trailing earnings.

Gujarat Themis Biosyn has achieved a new 52-week high, reflecting its strong position in the pharmaceuticals and biotechnology sector. The stock has shown consistent upward momentum, trading above key moving averages. In the broader market, the Sensex is also experiencing positive trends, with mega-cap stocks driving gains.

Gujarat Themis Biosyn has reached an all-time high, highlighting its strong performance in the pharmaceuticals and biotechnology sector. The company has shown impressive growth, with significant increases over the past month and year, and its stock is trading above key moving averages, indicating a robust upward trend.

Gujarat Themis Biosyn has achieved a new 52-week high of Rs. 465.3, reflecting a strong performance with a 51.85% increase over the past year. The stock remains resilient, trading above key moving averages, while the broader market also shows bullish trends, highlighted by the Sensex reaching a new high.

Gujarat Themis Biosyn's stock reached an all-time high of Rs. 465.3 on October 23, 2025, showcasing strong growth in the pharmaceuticals sector. Over the past year, it has increased by 50.98%, significantly outperforming the Sensex, and has shown remarkable gains over three and five years.

Gujarat Themis Biosyn has reached an all-time high of Rs. 443, reflecting its strong position in the Pharmaceuticals & Biotechnology sector. The stock has shown consistent growth, outperforming its sector and demonstrating impressive returns over various time frames, highlighting the company's operational capabilities and market strength.

Gujarat Themis Biosyn has achieved a new 52-week high, reflecting strong performance in the small-cap pharmaceutical sector. The stock has shown consistent upward momentum over the past week and has significantly outperformed the broader market, delivering impressive returns over the past year.

Gujarat Themis Biosyn has achieved a new 52-week high of Rs. 438.95, reflecting strong performance in the Pharmaceuticals & Biotechnology sector. The stock has shown resilience with a consecutive four-day gain and is trading above key moving averages, indicating a positive trend. The broader market also saw significant recovery.

Gujarat Themis Biosyn reached an all-time high on October 17, 2025, showcasing its strong position in the Pharmaceuticals & Biotechnology sector. The stock has consistently gained over the past days, significantly outperforming the Sensex and demonstrating impressive year-to-date and annual growth metrics.

Gujarat Themis Biosyn has achieved a new 52-week high of Rs. 438.5, reflecting strong performance in the pharmaceuticals sector. The stock has gained consistently over three days, with a total return of 5.26%. It is trading above key moving averages, while the broader market also shows positive trends.

Gujarat Themis Biosyn has reached an all-time high, reflecting its strong position in the Pharmaceuticals & Biotechnology sector. The stock has shown significant gains over recent days and is trading above various moving averages, indicating robust performance and active investor engagement. Its year-to-date performance notably exceeds that of the Sensex.

Gujarat Themis Biosyn has achieved a new 52-week high of Rs. 434.85, reflecting strong performance in the small-cap pharmaceutical sector. The stock has shown consistent gains over the past two days and is trading above key moving averages, indicating a positive trend amid a bullish market sentiment.

Gujarat Themis Biosyn has achieved an all-time high, reflecting strong performance in the pharmaceutical and biotechnology sector. The stock has shown consistent upward momentum, with significant gains over various time frames and is currently trading above multiple moving averages, indicating a bullish trend.